Business
MCAP: Q4 sales up 4%, but EBITA down 27% as Specialty Pharma faces royalty and pricing headwinds
MCAP: Q4 sales up 4%, but EBITA down 27% as Specialty Pharma faces royalty and pricing headwinds
About this update from Medcap Ab
Q4 2024 saw 4% sales growth, with strong performance in Assistive Tech and MedTech, but a sharp decline in Specialty Pharma due to lower royalties and pricing pressure. Adjusted EBITA fell 27% in Q4, but full-year EBITA rose 5%.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.